Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 126
3 154
2 49
1 24
NEB 5
Curative setting
A 53
C 2
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 35
Endocrine Tumours 21
Gastrointestinal Cancers 69
Genitourinary Cancers 70
Gynaecological Malignancies 39
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 11
Skin Cancers 29
TMB-H solid tumours 1
Thoracic Malignancies 82
Tumor agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 2
Skin Cancers 14
TMB-H solid tumours 0
Thoracic Malignancies 10
Tumor agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Durvalumab Platinum-based chemotherapy Placebo with platinum-based chemotherapy Durvalumab with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumours ≥4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements AEGEAN
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - AEGEAN

    A

    PRELIMINARY SCORE

    • A

    ADJUSTMENTS

    SCORE

    • F1

      A
    Tislelizumab Platinum + fluoropyrimidine-based ChT Placebo + platinum + fluoropyrimidine-based ChT Tislelizumab in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with HER-2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumours express PD‑L1 with a tumour area positivity (TAP) score ≥ 5% RATIONALE 305
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma HER2- , PD-L1 TAP ≥5% RATIONALE 305

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Ribociclib Non-steroidal aromatase inhibitor (NSAI) Non-steroidal aromatase inhibitor (NSAI) EMA/FDA: Ribociclib with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Additionally, FDA also approved the ribociclib and letrozole co-pack for the same indication. NATALEE
    Breast Cancer
    		 Early Breast Cancer HR-positive, HER2-negative NATALEE

    A

    PRELIMINARY SCORE

    • A

    ADJUSTMENTS

    SCORE

    • F1

      A
    Selpercatinib - Cabozantinib or Vandetanib Selpercatinib for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. LIBRETTO-531
    Endocrine Tumours
    		 Thyroid cancer - Medullary RET-mutant (M918T or other) LIBRETTO-531

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Serplulimab Carboplatin + Etoposide Placebo + Carboplatin + Etoposide Serplulimab in combination with carboplatin and etoposide is indicated for the first‑line treatment of adult patients with extensive‑stage small cell lung cancer (ES‑SCLC). ASTRUM-005
    Thoracic Malignancies
    		 Small-cell Lung Cancer - ASTRUM-005

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Osimertinib - Placebo FDA: Osimertinib for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. EMA: Osimertinib for adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum based chemoradiation therapy. LAURA
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR exon 19 deletions or exon 21 L858R mutations LAURA

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Pembrolizumab Pemetrexed + platinum-based Cht Pemetrexed + platinum-based Cht FDA: Pembrolizumab with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). EMA: Pembrolizumab, in combination with pemetrexed and platinum chemotherapy, is indicated for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma. KEYNOTE-483
    Thoracic Malignancies
    		 Pleural mesothelioma - KEYNOTE-483

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Pembrolizumab - Placebo For the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD- 1/PD-L1-containing regimen KEYNOTE-394
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - KEYNOTE-394

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Trastuzumab - Chemotherapy Patients with HER2-positive early breast cancer following surgery, ChT (neoadjuvant or adjuvant) and RT (if applicable) HERA
    Breast Cancer
    		 Early Breast Cancer HER2+ HERA

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel Neo-adjuvant HER2 overexpressed invasive ductal breast NeoSphere
    Breast Cancer
    		 Early Breast Cancer HER2+ NeoSphere

    C

    PRELIMINARY SCORE

    • pCR

    ADJUSTMENTS

    SCORE

    • F1

      C
    Trastuzumab emtansine (T-DM1) - Lapatinib + capecitabine As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy EMILIA
    Breast Cancer
    		 Breast Cancer HER2+ EMILIA

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel + placebo Treatment of patients with HER2-positive metastatic or locally recurrent unresectable BC who have not received previous anti-HER2 therapy or ChT for metastatic disease CLEOPATRA
    Breast Cancer
    		 Breast Cancer HER2+ CLEOPATRA

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Lapatinib Trastuzumab Lapatinib Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with HR- metastatic disease that has progressed on prior trastuzumab therapy of therapies in combination with ChT EGF104900
    Breast Cancer
    		 Breast Cancer HER2+ HR- EGF104900

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Palbociclib Fulvestrant Fulvestrant + placebo Patients with hormone receptor-positive, HER2-negative locally advanced or MBC who have received prior endocrine therapy (ET) PALOMA-3
    Breast Cancer
    		 Breast Cancer HR+ HER2- PALOMA-3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Palbociclib Letrozole Letrozole + placebo Treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor PALOMA-2
    Breast Cancer
    		 Breast Cancer HR+ HER2- PALOMA-2

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Palbociclib Letrozole Letrozole Treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor. PALOMA-1/TRIO-18
    Breast Cancer
    		 Breast Cancer HR+ HER2- PALOMA-1/TRIO-18

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Ribociclib Letrozole Letrozole + placebo Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONALEESA-2
    Breast Cancer
    		 Breast Cancer HR+ HER2- MONALEESA-2

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Lapatinib Capecitabine Capecitabine Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting EGF100151
    Breast Cancer
    		 Breast Cancer HER2+ EGF100151

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Bevacizumab Paclitaxel Paclitaxel First-line treatment of adult patients with metastatic breast cancer E2100
    Breast Cancer
    		 Breast Cancer - E2100

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Everolimus Exemestane Exemestane + placebo Treatment of HR+, HER2- advanced breast cancer, in combination with exemestane, in postmenpausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor BOLERO-2
    Breast Cancer
    		 Breast Cancer HR+ HER2- BOLERO-2

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Eribulin - Treatment of physician's choice As monotherapy for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after ≥1 ChT regimen for advanced disease EMBRACE
    Breast Cancer
    		 Breast Cancer - EMBRACE

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Eribulin - Treatment of physician's choice Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments Study 305 & Study 301 (Pooled analysis)
    Breast Cancer
    		 Breast Cancer HER2- Study 305 & Study 301 (Pooled analysis)

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Panitumumab FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) First-line treatment of patients with wild-type RAS mCRC PRIME
    Gastrointestinal Cancers
    		 Colorectal Cancer RAS-WT PRIME

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Cetuximab FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) Treatment of patients with EGFR-expressing, RAS wild-type mCRC CRYSTAL
    Gastrointestinal Cancers
    		 Colorectal Cancer EGFR-expressing RAS-WT CRYSTAL

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Cetuximab - Best supportive care Treatment of patients with EGFR-expressing, RAS wild-type mCRC in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan CO.17
    Gastrointestinal Cancers
    		 Colorectal Cancer KRAS-WT CO.17

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Bevacizumab IFL (irinotecan, leucovorin, fluorouracil) IFL (irinotecan, leucovorin, fluorouracil) + placebo Treatment of patients with metastatic carcinoma of the colon or rectum AVF2107g
    Gastrointestinal Cancers
    		 Colon and Rectal Cancer - AVF2107g

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Panitumumab FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) Second-line treatment of patients with wild-type RAS mCRC who have received first-line fluoropyrimidine-based ChT (excluding irinotecan) 20050181 study
    Gastrointestinal Cancers
    		 Colorectal Cancer RAS-WT 20050181 study

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Ramucirumab FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) + placebo Treatment of patients with mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine RAISE
    Gastrointestinal Cancers
    		 Colorectal Cancer - RAISE

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Bevacizumab FOLFOX4 (oxaliplatin, folinic acid, 5-fluorouracil) FOLFOX4 (oxaliplatin, folinic acid, 5-fluorouracil) Treatment of patients with metastatic carcinoma of the colon or rectum E3200
    Gastrointestinal Cancers
    		 Colorectal Cancer - E3200

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Panitumumab - Best supportive care Treatment of patients with wild-type RAS mCRC after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing ChT regimens Study 20020408
    Gastrointestinal Cancers
    		 Colorectal Cancer RAS-WT Study 20020408

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.